LONDON, UK — Prolonging the infusion of bivalirudin (Angiomax/Angiox, the Medicines Company) for several hours after the completion of PCI did not reduce the composite outcome of ischemic and bleeding ...
Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints--a composite of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results